Companies To Watch: Spruce Biosciences
Source: Life Science Leader
By Wayne Koberstein, Executive Editor, Life Science Leader
Follow Me On Twitter @WayneKoberstein
New agents versus rare endocrine disorders
SNAPSHOT
Spruce Biosciences is currently in mid-to-late-stage clinical development with the CRF1 receptor antagonist, tildacerfont, for treating two endocrine disorders: classic congenital adrenal hyperplasia (CAH) in adults and in children, and polycystic ovary syndrome (PCOS). Tildacerfont is an oral nonsteroidal small-molecule drug. Spruce has long-range plans for additional agents and indications in the same area.
access the Magazine Article!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.
Subscribe to Life Science Leader
X
Subscribe to Life Science Leader
This website uses cookies to ensure you get the best experience on our website. Learn more